100 related articles for article (PubMed ID: 2895220)
1. Chemotherapy for the primary treatment of osteosarcoma: population effectiveness over 20 years.
Gill M; McCarthy M; Murrells T; Silcocks P
Lancet; 1988 Mar; 1(8587):689-92. PubMed ID: 2895220
[TBL] [Abstract][Full Text] [Related]
2. The outcomes and prognostic factors in patients with osteosarcoma according to age: a Japanese nationwide study with focusing on the age differences.
Tsuda Y; Ogura K; Shinoda Y; Kobayashi H; Tanaka S; Kawai A
BMC Cancer; 2018 May; 18(1):614. PubMed ID: 29855362
[TBL] [Abstract][Full Text] [Related]
3. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
4. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
[TBL] [Abstract][Full Text] [Related]
5. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
6. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.
Nataraj V; Rastogi S; Khan SA; Sharma MC; Agarwala S; Vishnubhatla S; Bakhshi S
Clin Transl Oncol; 2016 Sep; 18(9):937-44. PubMed ID: 26742936
[TBL] [Abstract][Full Text] [Related]
7. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
8. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
9. Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Sun L; Li Y; Li H; Zhang J; Li B; Ye Z
Clin Ther; 2014 Apr; 36(4):567-78. PubMed ID: 24636527
[TBL] [Abstract][Full Text] [Related]
10. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival.
Ferrari S; Briccoli A; Mercuri M; Bertoni F; Picci P; Tienghi A; Del Prever AB; Fagioli F; Comandone A; Bacci G
J Clin Oncol; 2003 Feb; 21(4):710-5. PubMed ID: 12586810
[TBL] [Abstract][Full Text] [Related]
11. Osteosarcoma in New Zealand: an outcome study comparing survival rates between 1981-1987 and 1994-1999.
Curry H; Horne G; Devane P; Tobin H
N Z Med J; 2006 Sep; 119(1242):U2234. PubMed ID: 16998576
[TBL] [Abstract][Full Text] [Related]
12. [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
Delépine N; Alkallaf S; Cornille H; Markowska B; Delépine G
Ann Med Interne (Paris); 2003 Feb; 154(1):12-24. PubMed ID: 12746655
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
14. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.
Saeter G; Wiebe T; Wiklund T; Monge O; Wahlqvist Y; Engström K; Forestier E; Holmström T; Stenwig AE; Willén H; Brosjö O; Follerås G; Alvegård TA; Strander H
Acta Orthop Scand Suppl; 1999 Jun; 285():74-82. PubMed ID: 10429627
[No Abstract] [Full Text] [Related]
16. Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand.
Choeyprasert W; Natesirinilkul R; Charoenkwan P; Sittipreechacharn S
Asian Pac J Cancer Prev; 2013; 14(2):1101-6. PubMed ID: 23621194
[TBL] [Abstract][Full Text] [Related]
17. Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma.
Yong B; Tan P; Yin J; Zou C; Xie X; Wang J; Huang G; Wang Q; Shen J
World J Surg Oncol; 2012 Sep; 10():191. PubMed ID: 22985081
[TBL] [Abstract][Full Text] [Related]
18. Outcome of postradiation osteosarcoma does not correlate with chemotherapy response.
Lewis VO; Raymond K; Mirza AN; Lin P; Yasko AW
Clin Orthop Relat Res; 2006 Sep; 450():60-6. PubMed ID: 16906104
[TBL] [Abstract][Full Text] [Related]
19. Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry.
Winkler K; Bieling P; Bielack S; Delling G; Dose C; Jürgens H; Kotz R; Ritter J; Salzer-Kuntschik M
Clin Orthop Relat Res; 1991 Sep; (270):79-86. PubMed ID: 1715820
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
